Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Royalty Pharma Plc Cl A (NQ: RPRX ) 25.71 +0.04 (+0.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Royalty Pharma Plc Cl A < Previous 1 2 3 4 5 6 Next > Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 June 26, 2024 Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. Via InvestorPlace 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields June 12, 2024 Via Benzinga June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge June 05, 2024 Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. Via InvestorPlace Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Royalty Pharma plc Via GlobeNewswire NASDAQ:RPRX: good value for what you're paying. April 24, 2024 Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents. Via Chartmill Looking Into Royalty Pharma's Recent Short Interest April 04, 2024 Via Benzinga Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes June 03, 2024 From Royalty Pharma plc Via GlobeNewswire Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? May 28, 2024 Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. Via Benzinga Exposures Product Safety Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out May 28, 2024 The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. Via Investor's Business Daily Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million May 28, 2024 From Royalty Pharma plc Via GlobeNewswire NASDAQ:RPRX is an undervalued gem with solid fundamentals. March 29, 2024 ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals. Via Chartmill Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe May 23, 2024 Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. Via Benzinga Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline May 22, 2024 From Royalty Pharma plc; Cytokinetics Via GlobeNewswire 7 Dividend Stocks to Buy at a 52-Week Low May 20, 2024 For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low. Via InvestorPlace Royalty Pharma to Present at Upcoming Investor Conferences May 13, 2024 From Royalty Pharma plc Via GlobeNewswire RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Royalty Pharma Reports First Quarter 2024 Results May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment May 02, 2024 Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... Via Benzinga Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 April 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Second Quarter 2024 Dividend April 17, 2024 From Royalty Pharma plc Via GlobeNewswire 3 Pharma Stocks to Sell in April Before They Crash & Burn April 11, 2024 Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. Via InvestorPlace Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of) April 09, 2024 These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio. Via InvestorPlace April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio April 09, 2024 Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April. Via InvestorPlace The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio March 27, 2024 With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. Via InvestorPlace For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals. February 29, 2024 When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. Via Chartmill Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference February 28, 2024 From Royalty Pharma plc Via GlobeNewswire Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months February 16, 2024 Analysts are quite bullish about these beaten-down stocks. Via The Motley Fool Royalty Pharma Reports Q4 and Full Year 2023 Results February 15, 2024 From Royalty Pharma plc Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.